Exciting Update! Explore Myrtelle’s Insightful Slide Presentation on Gene Therapy for Canavan Disease Preliminary One-Year Results from Meeting on the Mesa.
Here is the link to Alliance for Regenerative Medicine's Youtube Channel. Mark Hurtt gave a presentation last month at Mesa, here is the slideshow he presented with…
Article Date
November 30, 2023
This article is featured on another website.
Go to article
October 1, 2024
Myrtelle Announces Significant Reduction in N-Acetylaspartate (NAA), a Key Biomarker, in Patients Treated in Its Phase 1/2 Clinical Trial of the Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease
Myrtelle announces significant reductions in N-Acetylaspartate (NAA), a key biomarker for Canavan Disease.
October 1, 2024
Myrtelle Announces Significant Reduction in N-Acetylaspartate (NAA), a Key Biomarker, in Patients Treated in Its Phase 1/2 Clinical Trial of the Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease
Myrtelle announces significant reductions in N-Acetylaspartate (NAA), a key biomarker for Canavan Disease.